BERLIN—The European Medicines Agency on Friday recommended that the use of the coronavirus vaccine made by Pfizer and BioNTech be expanded to children ages 12 to 15, a decision that offers younger and less at-risk populations across the continent access to a COVID-19 shot for the first time during the pandemic.
Marco Cavaleri, who heads the EMA body that reviewed the vaccine, said the European Union regulator had received the necessary data to authorize the vaccine for younger teens and found it to be highly effective against COVID-19.
The decision needs to be rubber-stamped by the European Commission and individual national regulators, he said.
The recommendation follows similar decisions by regulators in Canada and the United States last month, as rich countries slowly approach their vaccination targets for adults and look to immunize as many people as possible.
The Pfizer-BioNTech COVID-19 vaccine was the first one granted authorization across the 27-nation EU when it was licensed for use in anyone 16 and over in December.
The EMA’s recommendation that the vaccine’s authorization be expanded to children was based on a study in more than 2,000 adolescents in the United States that showed the vaccine was safe and effective. Researchers will continue to monitor the shot’s long-term protection and safety in the children for another two years.
But the World Health Organization has criticized rich countries for moving on to vaccinate their younger and less at-risk populations, saying that the extremely limited number of COVID-19 vaccines should instead be shared with poor countries so they too can protect their health workers and those most vulnerable.
Other vaccine makers also are studying whether their shots are safe and protective in children. Earlier this week, Moderna Inc. said its shot strongly protects children as young as 12; it said it would submit a request for emergency use authorization to the U.S. Food and Drug Administration next month.
Another U.S. company, Novavax, has a COVID-19 vaccine in late-stage development and just began a study in 12- to 17-year-olds.
Both Moderna and Pfizer-BioNTech have been testing their vaccines in children from age 11 down to six months; they get a lower dose than what teens and adults receive.
China’s Sinovac has also submitted early data to the country’s regulators, hoping to prove its vaccine is safe in children as young as 3.
